Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss - News

Semaglutide keeps making headlines, but this time it’s going head-to-head with a device. A new study shows endoscopic sleeve gastroplasty (ESG) beat out oral semaglutide for short-term weight loss. The numbers? ESG patients dropped more weight than those using oral semaglutide, at least in the early months.

No big surprise. ESG is a minimally invasive procedure that physically reduces stomach volume. You’d expect strong results up front. But oral semaglutide isn’t going anywhere. The research peptide is still making waves for its ability to drive significant weight loss with no surgery required.

Key details from the news:

Here’s the real takeaway for the peptide research crowd: semaglutide holds up surprisingly well, considering it’s a non-invasive research compound. The fact that a peptide can compete with a procedure is a win for the field, and it raises plenty of questions for future protocols. How will these two approaches stack up after one year? What about combination strategies?

For anyone interested in exploring research on semaglutide, check out the semaglutide page. If you’re comparing sources or suppliers, the vendor directory is worth a look.

Short-term, ESG takes the lead. But semaglutide’s performance as a research peptide keeps it front and center for the weight loss research community. This isn’t the last time these two will be compared.